File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Current management of stage IV nasopharyngeal carcinoma without distant metastasis

TitleCurrent management of stage IV nasopharyngeal carcinoma without distant metastasis
Authors
KeywordsImmunotherapy
Targeted therapy
Radiotherapy
Nasopharyngeal carcinoma
Prognosis
Chemotherapy
Issue Date2020
Citation
Cancer Treatment Reviews, 2020, v. 85, article no. 101995 How to Cite?
Abstract© 2020 Elsevier Ltd Up to one in four patients with nasopharyngeal carcinoma present with non-metastatic stage IV disease (i.e. T4 or N3). Distinct failure patterns exist, despite the routine adoption of contemporary treatment modalities such as intensity modulated radiotherapy and systemic chemotherapy. Concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy or induction chemotherapy followed by CCRT are commonly employed in this setting, with the latter emerging as the preferred option. Additionally, emerging radiation technologies like proton therapy has become available offering new opportunities for prevention of radiation-induced side effects. This article reviews not only the current treatment strategies, but also discusses novel ways to tackle this challenging disease with respect to the patterns of failure.
Persistent Identifierhttp://hdl.handle.net/10722/282118
ISSN
2020 Impact Factor: 12.111
2020 SCImago Journal Rankings: 4.278
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNg, Wai Tong-
dc.contributor.authorCorry, June-
dc.contributor.authorLangendijk, Johannes A.-
dc.contributor.authorLee, Anne W.M.-
dc.contributor.authorMäkitie, Antti-
dc.contributor.authorMendenhall, William M.-
dc.contributor.authorRinaldo, Alessandra-
dc.contributor.authorRodrigo, Juan P.-
dc.contributor.authorSaba, Nabil F.-
dc.contributor.authorSmee, Robert-
dc.contributor.authorStrojan, Primož-
dc.contributor.authorSuárez, Carlos-
dc.contributor.authorVermorken, Jan B.-
dc.contributor.authorFerlito, Alfio-
dc.date.accessioned2020-04-29T07:36:06Z-
dc.date.available2020-04-29T07:36:06Z-
dc.date.issued2020-
dc.identifier.citationCancer Treatment Reviews, 2020, v. 85, article no. 101995-
dc.identifier.issn0305-7372-
dc.identifier.urihttp://hdl.handle.net/10722/282118-
dc.description.abstract© 2020 Elsevier Ltd Up to one in four patients with nasopharyngeal carcinoma present with non-metastatic stage IV disease (i.e. T4 or N3). Distinct failure patterns exist, despite the routine adoption of contemporary treatment modalities such as intensity modulated radiotherapy and systemic chemotherapy. Concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy or induction chemotherapy followed by CCRT are commonly employed in this setting, with the latter emerging as the preferred option. Additionally, emerging radiation technologies like proton therapy has become available offering new opportunities for prevention of radiation-induced side effects. This article reviews not only the current treatment strategies, but also discusses novel ways to tackle this challenging disease with respect to the patterns of failure.-
dc.languageeng-
dc.relation.ispartofCancer Treatment Reviews-
dc.subjectImmunotherapy-
dc.subjectTargeted therapy-
dc.subjectRadiotherapy-
dc.subjectNasopharyngeal carcinoma-
dc.subjectPrognosis-
dc.subjectChemotherapy-
dc.titleCurrent management of stage IV nasopharyngeal carcinoma without distant metastasis-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ctrv.2020.101995-
dc.identifier.pmid32113080-
dc.identifier.scopuseid_2-s2.0-85079900655-
dc.identifier.hkuros322769-
dc.identifier.volume85-
dc.identifier.spagearticle no. 101995-
dc.identifier.epagearticle no. 101995-
dc.identifier.eissn1532-1967-
dc.identifier.isiWOS:000528486300008-
dc.identifier.issnl0305-7372-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats